Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer

We recently published 10 Stocks Stealing Wall Street’s Spotlight. Metsera Inc. (NASDAQ:MTSR) is one of the top performers on Monday.

Shares of Metsera Inc. (NASDAQ:MTSR) jumped to a new all-time high on Monday, as investors gobbled up shares following news that it was set to be acquired by Pfizer Inc. (NYSE: PFE) for a potential transaction value of more than $7 billion.

During the session, Metsera Inc. (NASDAQ:MTSR) soared to its highest price of $54.46 before trimming gains to close the day just up by 60.80 percent at $53.58 apiece.

Photo by Silvan Schuppisser on Unsplash

In a statement, the company said it entered into a definitive agreement with Pfizer for the acquisition of all of its outstanding shares at a price of $47.50 apiece.

Additionally, the agreement includes a non-transferable contingent value right (CVR) entitling Metsera Inc. (NASDAQ:MTSR) shareholders to potential additional payments of up to $22.50 per share if it achieves three specific clinical milestones: $5 per share following the Phase 3 clinical trial start of Metsera’s MET-097i+MET-233i combination; $7 per share following Food and Drug Administration (FDA) approval of Metsera’s monthly MET-097i monotherapy; and $10.50 per share following FDA approval of Metsera’s monthly MET-097i+MET-233i combination, if achieved.

The transaction is expected to close in the fourth quarter of 2025.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.